FDA Says Pfizer COVID-19 Vaccine Looks Effective for Young Kids

Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S. weighs beginning vaccinations in youngsters. The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11. The agency will ask a panel of outside vaccine experts to vote on that question. In their analysis, FDA scientists concluded that in almost every scenario the vaccine’s benefit for preventing hospitalizations and death from COVID-19 would outweigh any serious potential side effects in children. But agency reviewers stopped short of calling for Pfizer’s shot to be authorized. [time-brightcove not-tgx=”true”] The agency will put that question to its panel of independent advisers next Tuesday and weigh their advice before making its own decision. If the FDA authorizes the shots, the Centers for Disease Control and Prevention will make additional recommendations on who should receive them the first week of November. Children could begin vaccinations early next month — with the first youngsters in line fully protected by Christmas. Full-strength Pfizer shots already are recommended for anyone 12 or older, but pediatricians and many parents are anxiously awaiti...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 wire Source Type: news

Related Links:

World J Cardiol. 2021 Oct 26;13(10):556-565. doi: 10.4330/wjc.v13.i10.556.ABSTRACTCoronavirus disease has unarguably been the largest pandemic of recent times. Over 150 million cases have occurred worldwide, and more than 3 million have succumbed to the disease. Cardiac manifestations can have varied presentations from an asymptomatic troponin rise to fulminant myocarditis. The pathogenesis of myocardial damage could be direct or indirect, including inflammation, coronary spasm, plaque rupture, and cytokine storm. Thromboembolism is also an important feature of cardiovascular affliction with both arterial and venous system...
Source: World Journal of Cardiology - Category: Cardiology Authors: Source Type: research
With emergency use authorization for the Pfizer-BioNTech COVID vaccine newly approved for children 5-11, many parents are asking the question—should we vaccinate our kids? To be fair, many parents may have already made up their mind on this topic with the majority not rushing to get their kids vaccinated. Much of the argument against vaccinating this younger age group is that COVID-19 just doesn’t seem to cause a high likelihood of significant illness among immunocompetent children. Thankfully, purely as a percentage of total cases, this does hold true. To date, over six million children in the U.S. have contra...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
With emergency use authorization for the Pfizer-BioNTech COVID vaccine newly approved for children 5-11, many parents are asking the question—should we vaccinate our kids? To be fair, many parents may have already made up their mind on this topic with the majority not rushing to get their kids vaccinated. Much of the argument against vaccinating this younger age group is that COVID-19 just doesn’t seem to cause a high likelihood of significant illness among immunocompetent children. Thankfully, purely as a percentage of total cases, this does hold true. To date, over six million children in the U.S. have contra...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
AbstractThe ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as  air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can resul t in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Based on reports from China, we know that most COVID-19 patients (about 80%) will develop mild flulike symptoms, including fever, dry cough, and body aches that can be managed at home. 20% will develop more serious symptoms, such as pneumonia requiring hospitalization, with about a quarter of these requiring ICU-level care. Initial reports focused on the respiratory effects of COVID-19, such as pneumonia and difficulty breathing. But more recent literature has described serious cardiovascular complications occurring in about 10% to 20% of hospitalized patients. Someone with pre-existing heart disease who becomes ill with C...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Heart Health Hypertension and Stroke Infectious diseases Source Type: blogs
More News: Academies | Cardiology | Centers for Disease Control and Prevention (CDC) | Children | Coronavirus | COVID-19 | Education | Food and Drug Administration (FDA) | Health | Heart | Myocarditis | Pandemics | Pediatrics | Pfizer | Primary Care | Science | Statistics | Study | Universities & Medical Training | Vaccines